Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6188776 | Reproductive BioMedicine Online | 2015 | 9 Pages |
Abstract
This prospective, multicentre, observational study assessed usability and utility (co-primary endpoints) of the consistency in r-hFSH starting doses for individualized treatment (CONSORT) calculator in French routine clinical practice. Physicians first planned their recombinant human follicle-stimulating hormone (r-hFSH) starting dose. The CONSORT calculator was then used to recommend a starting dose. Data were collected for 197 women aged 18-35 years undergoing ovarian stimulation. The usability rate was high: 44/45 (97.8%) physicians found CONSORT user-friendly and easy to use for â¥75% of patients. Utility data showed that physicians followed the CONSORT recommendation for 89/197 (45.2%) patients. Reasons given for not following the CONSORT-calculated dose (N = 108) included: the CONSORT-calculated dose was too divergent from the planned dose (48.1%; 52/108) and/or the CONSORT-calculated dose did not correspond to the patient profile (46.3%; 50/108). The mean ± SD starting dose of r-hFSH planned by physicians was 163.9 ± 51.2 IU; the mean (SD) starting dose recommended by the CONSORT calculator was 119.7 ± 20.9 IU and the mean (SD) dose actually prescribed to patients was 151.7 ± 51.1 IU. Despite low physician-reported utility in this study, post-hoc analyses suggest the CONSORT calculator has potential for use in routine clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jean Luc Pouly, François Olivennes, Nathalie Massin, Médéric Celle, Natacha Caizergues, Francis Contard, French CONSORT Study Group French CONSORT Study Group,